InMode Ltd. (NASDAQ: INMD) announced that its board of directors authorized a new share repurchase program for up to 6.38 million ordinary shares, representing approximately 10% of the company's total shares outstanding.

The medical technology company repurchased approximately $127.4 million of its outstanding ordinary shares through share repurchase programs in 2025. The company stated it continues to generate cash flow and views repurchasing shares at current valuations as an attractive capital allocation strategy.

InMode expects to fund the repurchases with available cash. The company may make repurchases from time to time in the open market or through other permitted means, subject to market conditions and applicable legal requirements. The program may be modified, suspended, or discontinued at the company's discretion.

The Yokneam, Israel-based company develops, manufactures, and markets devices using radio frequency technology for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology applications.

Management indicated it remains focused on maintaining a disciplined approach to capital allocation while continuing to evaluate additional share repurchase programs and other capital allocation opportunities.